Steady State Pharmacokinetics (PK) of Fosamprenavir (FPV) Alone or in Combination With Low Dose Ritonavir (/r) (1400mg BID, 1400mg/100mg QD or 700/100mg BID) and the Chemokine Receptor 5 (CCR5) Entry Inhibitor Maraviroc (MVC) 300mg BID in Healthy Volunteers
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2016
At a glance
- Drugs Maraviroc (Primary) ; Fosamprenavir; Ritonavir
- Indications HIV infections
- Focus Pharmacokinetics
- 30 Dec 2008 Planned number of patients changed from 48 to 45 as reported by ClinicalTrials.gov.
- 30 Dec 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Oct 2008 New trial record.